CA2393588A1 - Solid oral dosage form - Google Patents

Solid oral dosage form Download PDF

Info

Publication number
CA2393588A1
CA2393588A1 CA002393588A CA2393588A CA2393588A1 CA 2393588 A1 CA2393588 A1 CA 2393588A1 CA 002393588 A CA002393588 A CA 002393588A CA 2393588 A CA2393588 A CA 2393588A CA 2393588 A1 CA2393588 A1 CA 2393588A1
Authority
CA
Canada
Prior art keywords
liquid
dosage form
oral dosage
solid
solid oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002393588A
Other languages
English (en)
French (fr)
Inventor
Beth A. Burnside
Henry H. Flanner
Xiaodi Guo
Rong Kun Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Supernus Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2393588A1 publication Critical patent/CA2393588A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002393588A 1999-12-08 2000-12-06 Solid oral dosage form Abandoned CA2393588A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/457,248 US6793934B1 (en) 1999-12-08 1999-12-08 Solid oral dosage form
US09/457,248 1999-12-08
PCT/US2000/042606 WO2001041737A2 (en) 1999-12-08 2000-12-06 Solid oral dosage form

Publications (1)

Publication Number Publication Date
CA2393588A1 true CA2393588A1 (en) 2001-06-14

Family

ID=23815987

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002393588A Abandoned CA2393588A1 (en) 1999-12-08 2000-12-06 Solid oral dosage form

Country Status (6)

Country Link
US (1) US6793934B1 (https=)
EP (1) EP1235559A2 (https=)
JP (1) JP2003530314A (https=)
AU (1) AU4139701A (https=)
CA (1) CA2393588A1 (https=)
WO (1) WO2001041737A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004001A1 (en) 2001-07-06 2003-01-16 Lifecycle Pharma A/S Controlled agglomeration
ITMI20012366A1 (it) * 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
SE0200895D0 (sv) * 2002-03-22 2002-03-22 Astrazeneca Ab New pharmaceutical composition
RU2387451C2 (ru) * 2002-05-10 2010-04-27 Ф.Хоффманн-Ля Рош Аг Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
ITMI20021392A1 (it) * 2002-06-25 2003-12-29 Nicox Sa Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'
JP2006056781A (ja) * 2002-11-15 2006-03-02 Bioserentack Co Ltd 界面活性剤を含む固形化製剤
KR20060119971A (ko) 2003-09-11 2006-11-24 제노포트 인코포레이티드 Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방
CA2540225C (en) * 2003-10-31 2012-03-06 Takeda Pharmaceutical Company Limited Solid preparation of pioglitazone, glimepiride and a polyoxyethylene sorbitan fatty acid ester
US20050181049A1 (en) * 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
US7337483B2 (en) * 2004-01-23 2008-03-04 Allen Medical Systems, Inc. Surgical positioning apparatus
US20060051409A1 (en) * 2004-09-08 2006-03-09 Groenewoud Pieter J Bezonatate liquid hard capsule dosage form
US20060222700A1 (en) * 2005-04-05 2006-10-05 Groenewoud Pieter J Tablet and capsule form of liquid active ingredient
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20080207745A1 (en) * 2007-02-24 2008-08-28 Sri International Orally-absorbed formulation for paromomycin
US8445545B2 (en) * 2008-05-07 2013-05-21 Nicholas DeSica Pharmaceutical composition, method of preparation and methods of treating aches/pains
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US8357398B2 (en) * 2009-10-21 2013-01-22 Alitair Pharmaceuticals Inc. Benzonatate compositions and methods of use
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
PL2696687T3 (pl) 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
CN104203238A (zh) 2011-11-10 2014-12-10 纪念斯隆-凯特琳癌症中心 用亚苄基苯甲酰肼治疗卵巢癌
WO2013095111A1 (en) 2011-12-14 2013-06-27 Disphar International B.V. Simethicone formulation
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
PT2827845T (pt) 2012-03-22 2019-03-29 Novo Nordisk As Composições compreendendo um agente de entrega e sua preparação
ES2965469T3 (es) 2012-03-22 2024-04-15 Novo Nordisk As Composiciones que comprenden un agente de suministro y preparación de estas
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
KR102290178B1 (ko) * 2013-03-13 2021-08-18 트리스 파마 인코포레이티드 벤조나테이트 변형 방출 고체 정제 및 캡슐
US9180104B2 (en) * 2013-03-13 2015-11-10 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
MA41620A (fr) 2015-05-14 2018-01-09 Abdi Ibrahim Ilac Sanayi Ve Ticaret A S Composition pharmaceutique comprenant de la siméthicone et de l'otilonium
WO2016200345A1 (en) 2015-06-12 2016-12-15 Santa Farma İlaç Sanayi̇ A. Ş. Oral pharmaceutical composition comprising otilonium bromide and simethicone with certain bulk density and improved dissolution characteristics.
US11938224B1 (en) 2016-04-08 2024-03-26 Tris Pharma Inc Benzonatate modified release solid tablets and capsules
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61186313A (ja) * 1985-02-12 1986-08-20 Dainippon Pharmaceut Co Ltd バルプロ酸ナトリウム製剤
JPH0696525B2 (ja) * 1985-10-02 1994-11-30 鐘紡株式会社 バルプロ酸ナトリウム徐放錠
US5182103A (en) * 1985-12-09 1993-01-26 Shiseido Company, Ltd. Magnesium aluminometasilicate coated composite powder and use thereof
US5075291A (en) 1989-11-22 1991-12-24 Ici Americas Inc. Crystalline sugar alcohol containing uniformly dispersed particulate pharmaceutical compound
ES2119748T3 (es) * 1990-03-23 1998-10-16 Yoshitomi Pharmaceutical Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
US5188836A (en) 1990-07-27 1993-02-23 Warner-Lambert Company Sustained release formulations
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5800834A (en) 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
PE20000066A1 (es) * 1997-12-22 2000-02-09 Schering Corp Formas de dosificacion solida de ribavirina administrables oralmente y proceso de fabricacion
DE69942205D1 (de) 1998-08-13 2010-05-12 Cima Labs Inc Microemulsionen als feste dosisformen zur oralen verabreichung
MY125803A (en) * 1998-11-06 2006-08-30 Fuji Chem Ind Co Ltd A tocotrienol-containing powder, a process for preparing it and a tablet comprising compressed said powder into a tablet form
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
KR100618234B1 (ko) * 1998-12-23 2006-09-01 알자 코포레이션 다공성 입자를 포함하는 제형

Also Published As

Publication number Publication date
US6793934B1 (en) 2004-09-21
WO2001041737A2 (en) 2001-06-14
EP1235559A2 (en) 2002-09-04
WO2001041737A3 (en) 2002-01-03
JP2003530314A (ja) 2003-10-14
AU4139701A (en) 2001-06-18

Similar Documents

Publication Publication Date Title
US6793934B1 (en) Solid oral dosage form
JP2003530314A5 (https=)
Nazzal et al. Controlled release of a self-emulsifying formulation from a tablet dosage form: Stability assessment and optimization of some processing parameters
CN100579514C (zh) 通过受控制的凝聚而制备颗粒物的方法以及提高生物利用度的方法
CN101365428B (zh) 可负载崩解片剂
EP1032373B1 (en) Drug delivery systems utilizing liquid crystal structures
US20020102301A1 (en) Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
CN101137365A (zh) 包含西罗莫司和/或其类似物的药物组合物
US20090060993A1 (en) Solid pharmaceutical composition for enhanced delivery of coenzyme q-10 and ubiquinones
US20090263479A1 (en) Formulations for poorly permeable active pharmaceutical ingredients
JP2003520772A (ja) 脂質調節剤を含む新規製剤
EP0368247A2 (en) Controlled release preparations
WO2005053689A2 (en) Pharmaceutical compositions comprising lercanidipine
JP2008531509A (ja) 医薬品成分の改良された分散性を有する錠剤
US20050037073A1 (en) Solid self-emulsifying dosage form for improved delivery of poorly soluble hydrophobic compounds and the process for preparation thereof
WO2019219823A1 (en) Solid dispersion containing ritonavir
WO2004062643A1 (en) Dry dispersions
NZ504353A (en) Porous greasy or non-greasy hydroxyapatite ceramic particles and a greasy, oily or sticky excipient as carriers for drug substances
MX2007012124A (es) Formulaciones mejoradas de fenofibrato.
JPH0625055B2 (ja) 持続性錠剤
WO2006037344A1 (en) Pharmaceutical compositions comprising fenofibrate and atorvastatin
US20070077309A1 (en) Banded controlled release nanoparticle active agent formulation dosage forms and methods
Hasan et al. Effect of self-microemulsifying lipid formulations on the dissolution and compaction profiles of tablets containing theophylline; a BCS class I compound
PL197447B1 (pl) Kompozycje lewosimendanu o kontrolowanym uwalnianiu do podawania doustnego
WO2025163665A1 (en) Stable pharmaceutical compositions of abiraterone

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead